SPARCL1 has been investigated in Alzheimer’s disease and multiple sclerosis, where its roles in neuroinflammation, astrocytic activation, and synaptic remodeling have been highlighted in experimental studies [25,26]. Here, SPARCL1 is linked to early-onset autosomal dominant Alzheimer disease.